<DOC>
	<DOCNO>NCT01597310</DOCNO>
	<brief_summary>This study assess effect dexpramipexole pharmacokinetics ( PK ) CYP2C9 probe substrate warfarin healthy volunteer .</brief_summary>
	<brief_title>Dexpramipexole Warfarin Drug Drug Interaction ( DDI ) Study</brief_title>
	<detailed_description>This single center open label study assess effect Dexpramipexole PK Warfarin Healthy Volunteers . The goal study follow : assess effect dexpramipexole pharmacodynamics ( PD ) warfarin , assess safety tolerability dexpramipexole administer alone , warfarin , assess PK dexpramipexole administer alone ; explore influence genetic variation PK international normalize ratio ( INR ) warfarin administer alone , dexpramipexole ; explore influence genetic variation PK dexpramipexole administer alone .</detailed_description>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Subjects , opinion investigator , healthy determine medical history , physical examination , 12 Lead ECG . Adult males/females age 18 55 year inclusive . Male female subject childbearing age must practice effective contraception study 90 day last dose study drug . History malignant disease , include solid tumor hematologic malignancy . Clinically significant current active infection serious infection . History gastrointestinal bleeding , peptic ulcer disease , hemorrhoid epistaxis . Personal family history bleed disorder , and/or coagulation profile result outside normal limit . Known allergy hypersensitivity warfarin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>